Valuation: Altimmune, Inc.

Market Cap 558M 488M 450M 415M 782M 53.75B 799M 5.38B 2.12B 26.32B 2.1B 2.05B 90.62B P/E 2026 *
-4.26x
P/E 2027 * -3.79x
Enterprise Value 175M 153M 141M 130M 245M 16.86B 251M 1.69B 664M 8.26B 658M 643M 28.43B EV / Sales 2026 *
42,709x
EV / Sales 2027 * -
Free-Float
99.59%
Yield 2026 *
-
Yield 2027 * -
1 day+0.70%
1 week-5.90%
Current month-5.59%
1 month+6.30%
3 months-18.00%
6 months-32.31%
Current year-20.50%
1 week 2.77
Extreme 2.77
3.02
1 month 2.74
Extreme 2.74
3.4
Current year 2.56
Extreme 2.56
6.44
1 year 2.56
Extreme 2.56
6.44
3 years 2.09
Extreme 2.09
14.84
5 years 2.09
Extreme 2.09
23.49
10 years 1.51
Extreme 1.51
237.3
Manager TitleAgeSince
Chief Executive Officer 58 01/01/2026
Director of Finance/CFO 70 11/11/2024
Chief Tech/Sci/R&D Officer - 01/05/2025
Director TitleAgeSince
Director/Board Member 58 01/09/2003
Chairman 78 01/01/2018
Director/Board Member 76 01/07/2012
Date Insider Type Main position Quantity % Market Cap.
5/1/26 A Free

Director

48,800 0.0251%
5/1/26 A Free

Director

48,800 0.0251%
5/1/26 A Free

Director

48,800 0.0251%
Change 5-day change 1-year change 3-year change Capi.($)
+0.70%-5.90%-29.66%-8.89% 558M
+0.24%-1.54%+52.85%+71.85% 53.83B
-7.17%-4.39%+42.72%+73.32% 52.1B
+0.80%-6.31%+5.62%+417.78% 23.48B
-0.09%-0.01%-16.85%-15.41% 23.13B
-5.95%-2.58%+29.53%-9.47% 19.36B
-1.14%+0.03%+31.67%-30.65% 17.56B
-5.16%-7.00%+168.44%+314.96% 15.2B
-6.91%-5.83%+25.17%+644.30% 14.83B
+0.43%-1.03%+25.75%+189.74% 14.06B
Average -2.43%-2.95%+33.52%+164.75% 23.41B
Weighted average by Cap. -2.79%-2.36%+39.38%+142.76%

Financials

2026 *2027 *
Net sales 4.1K 3.58K 3.31K 3.05K 5.74K 395K 5.87K 39.52K 15.54K 193K 15.4K 15.06K 666K -
Net income -112M -97.69M -90.15M -83.09M -157M -10.77B -160M -1.08B -424M -5.27B -420M -411M -18.15B -139M -122M -112M -103M -195M -13.41B -199M -1.34B -528M -6.57B -523M -511M -22.6B
Net Debt -383M -335M -309M -285M -537M -36.89B -549M -3.69B -1.45B -18.07B -1.44B -1.41B -62.19B -256M -224M -206M -190M -359M -24.65B -367M -2.47B -970M -12.07B -961M -940M -41.56B
Logo Altimmune, Inc.
Altimmune, Inc. is a late clinical-stage biopharmaceutical company. The Company is developing novel therapies for serious liver diseases. Its lead product candidate, pemvidutide (formerly ALT-801), is a balanced 1:1 glucagon/GLP-1 dual receptor agonist in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD) and alcohol-associated liver disease (ALD). The activation of glucagon receptors results in direct effects on the liver, including reductions in liver fat, inflammation and fibrosis, whereas the activation of GLP-1 receptors mediates suppression of appetite and reduction of cravings as well as metabolic effects such as weight loss. It has completed phase II development of pemvidutide. It also develops and commercializes surfactant-functionalized (EuPort domain) incretin-based peptide therapeutics, including (GLP-1-glucagon)/oxyntomodulin, and variants.
Employees
57
Date Price Change Volume
17/07/26 $2.870 +0.70% 2,963,768
16/07/26 $2.850 -4.36% 2,995,414
15/07/26 $2.980 +1.71% 2,862,398
14/07/26 $2.930 -2.01% 3,298,979
13/07/26 $2.990 -1.97% 2,457,098
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
2.870USD
Average target price
15.45USD
Spread / Average Target
+438.33%

Quarterly revenue - Rate of surprise